News

Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.

In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.

DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.

Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.

Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.

An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.

Simvera PSP applies queueing science so manufacturers can test the cost and patient impact of hub staffing decisions before locking them in.

Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.

As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.

In the final installment of his interview with Pharmaceutical Commerce, Cencora's Ameer Ali outlines how supply chain stakeholders should prepare systems, processes and trading partners for the shift to NDC-12.

In the final installment of his interview with Pharmaceutical Commerce, Cencora's Gregg Gorniak looks back at DSCSA's five-year evolution and where serialized data is creating value beyond compliance.

Authenticx CEO Amy Brown on why patient support AI needs continuous oversight, not just adoption.

HDA's Kala Shankle unpacks the biggest open question on preemption and offers a two-step playbook for wholesalers and 3PLs preparing for national licensure.

In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.

Twenty-six manufacturers now hold most-favored-nation agreements, and the commitments attached to the pricing terms may matter more than the prices themselves.

Cardinal Health's Liberty Dewey outlines the four parallel work streams driving the NDC-12 transition, and why the biggest risk sits in trading partner handoffs rather than any single system.

Joe Reynolds, Head of User Experience Services at Noble, breaks down what it really takes for pharmaceutical companies to move therapy from the clinic into the patient's home.

Logan Melchione shares how ClaimGuardRx gives account teams a fast, conversational way to tackle diversion and fraud together, and what that means for clients and patients.

Bryan Dennison breaks down the purpose-built technology behind ClaimGuardRx and how its detect-and-respond design keeps manufacturers ahead of evolving diversion tactics.

Matt Turner shares how ClaimGuardRx is redefining patient affordability by turning claims data into a proactive defense against maximizers and accumulators.

Overhaul's Danny Ramon argues that quality and regulatory teams, not just logistics, need faster protocols and more accessible stability data, since stolen or compromised product that re-enters the supply chain through gray markets can ultimately reach patients.

Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.

Ed Schoonveld examines the uncertainty surrounding President Trump's MFN drug pricing agreements, stalled GENEROUS, GLOBE and GUARD proposals, and their ripple effects on ex-US drug launches.

AI-native operating systems present new capabilities to improve pharma supply chain operations.

Cencora's Gregg Gorniak on where DSCSA trading partners find shared value in compliance investment, and where that alignment breaks down.

In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings.

McKesson's Scott Mooney discusses the technical and operational challenges of DSCSA compliance, from linking ERP systems to EPCIS to recurring friction in 340B transaction data exchange.

HDA's Kala Shankle says a two-year national licensure runway for distributors could work, but only if states, the FDA and industry move in parallel.